Precision for Medicine and Trialbee Partner to Advance Complex Therapy Trials Toward Precision Medicine
Precision for Medicine and Trialbee are addressing complexities in clinical development through a new partnership that will aim to accelerate the future of precision medicine. Trialbee’s analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, aims to enhance patient enrollment with a focus on representative trial participants.
Trialbee HIVE is a real-world data-driven patient matching platform that uses global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
